Thomas J. Dietz, PhD
Chairman of the Board
Chairman and CEO of Waypoint Holdings, LLC
Thomas Dietz is Chairman and CEO of Waypoint Holdings, LLC, a diversified financial holdings and services company. Dr. Dietz was co-CEO then CEO and a Director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr. Dietz served as Head of the Investment Banking Division at Wedbush until November 2010. Prior to taking the CEO role at Pacific Growth, Dr. Dietz served as the Company’s Director of Equities Research and was an award-winning biotechnology and biopharmaceutical analyst. Dr. Dietz joined Pacific Growth in 1993. Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz also serves as the Chairman of AgBiome, LLC, and is a board member of Paratek Pharmaceuticals (PRTK:Nasdaq) and Leap Therapeutics (LEAP:Nasdaq) and several private companies.
Thomas Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.
Evan Loh, MD
President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc.
At Paratek, Evan Loh, M.D. has served as Chief Operating Officer since January 2017 and as President and Chief Medical Officer and a member of the Board of Directors since July 2014. Prior to the merger with Transcept Pharmaceuticals, Dr. Loh was appointed President in June 2014 and served as Chief Medical Officer and Chairman of the Board of Directors from June 2012 to June 2014. Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization. Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President, Multiple Therapeutic Areas where he was responsible for global development strategy and clinical operational deliverables. At Wyeth, he led the successful global registration programs for Torisel and Tygacil. He currently serves as Vice Chair of the Antimicrobials Working Group, an industry leading organization of biotech companies focused on antimicrobial development. Dr. Loh served as a director on the Board of Nivalis (Nasdaq: NVLS) from 2012 until the completion of its sale to Alpine Immunotherapeutics (Nasdaq: ALPN) in 2017. Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.
Eldon Mayer III, MBA
Executive Vice President and Chief Commercial Officer of Rigel Pharmaceuticals
Eldon Mayer is a pharmaceutical industry veteran with broad commercial experience which spans over two decades in large pharma and specialty pharma across oncology, inflammatory disease, pulmonary disease, dermatology and rare diseases, with multiple successful exits by acquisition.
Mr. Mayer is currently Executive Vice President and Chief Commercial Officer of Rigel Pharmaceuticals. Prior to joining Rigel, Mr. Mayer successfully led the commercial function at Questcor Pharmaceuticals, a specialty biopharma company that focused on serious, ultra-rare diseases. As head of commercial operations, Mr. Mayer relaunched Acthar® Gel (Repository Corticotropin Injection); repositioning the product, building out a specialty commercial team to over 400 people and growing annual sales to over $1 billion. Questcor was acquired by Mallinckrodt for approximately $5.6 billion in 2014. Prior to that, he held positions of increasing responsibility at a number of biopharma companies including Schering-Plough, ALZA, Chiron, and Connetics, in functional areas including strategic planning, marketing, sales, market research and analytics, operations and finance. Mr. Mayer serves as a member of the Board of Promet Therapeutics LLC and the National Community Oncology Dispensing Association. Mr. Mayer holds a BS in Finance from Fairleigh Dickinson University and an MBA in Marketing from Syracuse University.
Christine Murray, MS, RAC
Senior Vice President of Regulatory Affairs of Ultragenyx Pharmaceutical, Inc.
Christine Murray was appointed as a member of the Board in January 2019. Ms. Murray serves as Senior Vice President of Regulatory Affairs at Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Prior to joining Ultragenyx Pharmaceutical, Inc., Ms. Murray was Vice President of Regulatory Affairs at Raptor Pharmaceuticals, a company that developed products for serious, ultra-rare diseases, from 2015 to 2017. Raptor Pharmaceuticals was acquired by Horizon Pharma plc. in 2017. Ms. Murray also held positions of increasing responsibility at a number of biopharma companies including Achaogen, Inc. from 2011–2015, Alexza Pharmaceuticals, Inc. from 2008–2011, and Gilead Sciences, Inc. from 2004–2008, in Regulatory Affairs and Quality Assurance. Ms. Murray holds a BS in Biochemistry from Liverpool University, UK, an MS in Clinical Biochemistry from the University of Newcastle-upon-Tyne, UK, and a Regulatory Affairs Certification from the University of California Santa Cruz Extension.
Jeffrey S. Glenn, MD, PhD
Jeffrey Glenn is an Associate Professor of Medicine, Gastroenterology & Hepatology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering.
Dr. Glenn is an author on over 50 scientific articles and book chapters, is an inventor on over 30 issued and pending patent applications, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. His primary research interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. He is the principal investigator on multiple NIH grants, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory Committee.
Dr. Glenn’s work has focused on the function and cell biology of the hepatitis C virus (HCV) non-structural proteins, and has identified a collection of novel antiviral targets within HCV that can form the basis for new potential antiviral strategies. Dr. Glenn discovered the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses including as a trigger of virus assembly and a target for a promising antiviral treatment. Other interests include exploitation of hepatic stem cells, development of a small animal model for HCV, and engineered human liver tissues.
Jeffrey Glenn received his undergraduate degree from the University of California, Berkeley summa cum laude in Biochemistry and French Civilization, and both a Ph.D. in Biochemistry and Biophysics and M.D. from the University of California, San Francisco Medical Scientist Training Program. He completed an internship and residency in internal medicine, as well as a fellowship in gastroenterology, at Stanford University’s School of Medicine.
David A. Cory, RPh, MBA
President and Chief Executive Officer, Director, Business Founder
David Cory is an industry veteran with over 25-years of experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational performance, including 5 successful Orphan Designation drug programs.
Cory is President and CEO, Director, and business founder of Eiger BioPharmaceuticals, leading the company since its founding in 2008 and responsible for negotiating the company’s multiple technology and product licenses from Stanford University, Merck, Nippon Kayaku, Janssen, BMS and The Progeria Research Foundation. Prior to Eiger, Cory was President and Chief Operating Officer of Prestwick Pharmaceuticals, an orphan CNS specialty pharmaceutical company, which was acquired by Biovail for $160 million in 2007. Previously, Cory was a Co-Founder at CoTherix, an orphan pulmonary arterial hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his biotech career at InterMune, focused on developing orphan products for idiopathic pulmonary fibrosis, where he was a Senior Vice President and a key executive in the company IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. InterMune was ultimately acquired by Roche for $8 billion in 2013. Cory spent over a decade in large pharma in positions of increasing responsibilities in commercial operations at Glaxo, Glaxo Wellcome, and Glaxo Smith Kline where he led teams in oncology, critical care, CNS, infectious disease and respiratory therapeutic areas, and directed 10 newly approved pharmaceutical product launches. Cory began his pharmaceutical career in sales at The Upjohn Company.
Cory earned a Bachelor of Science in Pharmacy from the University of Cincinnati, College of Pharmacy, was board certified in Pharmacy in the state of Ohio, and holds a Master’s Degree in Business Administration from the University of Maryland.
David Apelian, MD, PhD, MBA
CHIEF OPERATING OFFICER AND EXECUTIVE MEDICAL OFFICER
David Apelian brings extensive clinical development and regulatory experience, spanning 17 years between large pharma and biotechnology companies in all phases of development ranging from discovery to registration, across multiple therapeutic areas including gastroenterology, hepatology, immuno-oncology, infectious diseases, and rare diseases.
Dr. Apelian was most recently Executive VP and Chief Medical Officer of Achillion Pharmaceuticals, Inc., a position he held since 2013. At Achillion, he was responsible for creating portfolio strategy and managing the company’s clinical development programs. He was instrumental in securing a partnership between Achillion and J&J, which resulted in a $225 million equity investment. More recently, he led the rare disease development program for novel small-molecule complement factor D inhibitors for alternative pathway-mediated diseases. From 2005 to 2013, Dr. Apelian was Chief Medical Officer and subsequently head of all R&D and Regulatory Affairs for GlobeImmune. He was previously at Bristol-Myers Squibb where he served as Clinical Director and Medical Leader for development of Baraclude® (entecavir) for chronic HBV through NDA filing. Prior to that, Dr. Apelian was Clinical Director in the Department of Hepatology & Gastroenterology at Schering Plough, where he coordinated a supplemental NDA filing for interferon alpha-2b and ribavirin for the treatment of pediatric patients with chronic HCV.
Dr. Apelian completed his residency training in pediatrics at New York Hospital, Cornell Medical Center and is board certified in Pediatrics. He received a PhD in Biochemistry from Rutgers University, an MD from the University of Medicine and Dentistry of New Jersey and an MBA from Quinnipiac University. He earned a BA in Biochemistry from Rutgers University.
Amit K. Sachdev
Amit K. Sachdev is Chief Regulatory Officer at Vertex Pharmaceuticals, where he has served over the past decade in numerous executive leadership roles spanning the business as an executive officer and member of the Executive Committee. During this time, the Company has experienced seven-fold growth and successfully developed and commercialized four novel breakthrough medicines for patients with serious liver disease and for patients with a life-threatening lung disease called cystic fibrosis. Today, Vertex is one of the world’s leading global biotechnology companies with its headquarters in Boston, Massachusetts and London, England.
Over the prior decade, Mr. Sachdev held various senior executive appointments in government both at the U.S. Food and Drug Administration and in the U.S House of Representatives. He also practiced law first at the American Chemistry Council and at the law firm of Ropes and Gray.
Amit serves on several non-profit and philanthropic boards, including MassBIO, a biotechnology innovation association in Massachusetts, and Imagine and Answer, a charity group focused on supporting research into rare forms of low-grade pediatric brain cancer. In 2017, he joined the Board of Advisors for the Stanford Center for Longevity Studies.